I had the pleasure to sit on a panel at the Alzheimers Disease Research Summit in Session VI: Enabling Partnerships for Open Innovation: http://www.nia.nih.gov/about/events/2014/alzheimers-disease-research-summit-2015 . I had the opportunity to highlight some of the work RSC has done in terms of supporting (Open) Drug Discovery and working with Open PHACTS, PharmaSea and Open Source Drug Discovery.

1. Advancing Drug Discovery Through Open Science
Open
Collaboration
Open Data
Licensing
Computer
Modeling
Open
Models
and
Feedback
Web and
API Access
Pharma share precompetitive data/experience
How much data is lost or discarded?
What is the quality of the metadata?
How much data cannot be annotated?
Is open data licensing clear yet?
If more data were open…
If data could be validated…
If models could be made open…
If funding agencies required openness…
Could we advance Alzheimer’s Research?